FDA infant formula proposed QC batch-testing possibly "burdensome," Sandoz asserts.
This article was originally published in The Tan Sheet
Executive Summary
FDA INFANT FORMULA PROPOSED BATCH-TESTING "BURDENSOME," SANDOZ ARGUES, if it requires full analytical testing for every nutrient in each batch of formula. In Oct. 4 comments, Sandoz Nutrition tells the agency that it is unsure whether the proposed quality control procedures for infant formulas mean that: "a) the manufacturer must conduct full analytical testing on every nutrient in every batch; or b) the manufacturer would test each batch for a premix tracer plus full analytical testing on any nutrients added independently from premixes."
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning